AstraZeneca
rare disease highlights accelerating innovation across our pipeline high incidence of acute kidney injury after cardiac surgery driven by kidney where complement plays a key role next generation alfa with longer half life increased enzymatic activity higher and in exposure improved manufacturing process as potential first and only preventative treatment for opportunity to expand geographic reach and patient population in | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
30 of 45
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io